Lotte Holdings Bears 168 Billion KRW Burden in Biologics Capital Increase
Lotte Biologics announced on the 26th that it will conduct a paid-in capital increase by issuing 3,231,000 common shares to finance the construction costs of the Songdo Bio Campus Plant 1.
The capital increase will be conducted through a rights offering to existing shareholders, with an issue price of 65,000 KRW per share.
Among the approximately 210 billion KRW raised through the paid-in capital increase, Lotte Corporation will bear about 168 billion KRW.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Kim Young-hoon, the Problem Solver Who Averted Samsung Electronics' General Strike... Breakthrough Achieved Through the Power of Dialogue
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Lotte Corporation holds an 80% stake in Lotte Biologics, while Japan's Lotte Holdings holds 20%.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!["Please Help Us": How Much Do Those Bowing Deeply for Your Vote Really Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
